



Dividend Aristocrats Spotlight

West Pharmaceutical Services

West Pharmaceutical Services (NYSE: WST) has been an integral part of the healthcare industry for over a century. As a global leader, it specializes in containment and delivery systems for injectable medications, having supplied penicillin during WWII and COVID-19 vaccines during the pandemic. There's a strong chance you've encountered a West Pharma product.




Company Highlights

West Pharmaceutical has fortified its competitive leadership with its relentless commitment to quality. Given the paramount importance of patient safety and the reputational costs of recalls in the healthcare industry, their focus on quality is not just a selling point—it's a necessity. West Pharmaceutical sets itself apart by being a “full-service, value-added” supplier, reducing delivery times and costs while meeting the quality standards its customers expect.¹

West Pharmaceutical's quality-driven ethos and market leadership has resulted in consistently higher earnings power, with operating and net margins that double the average of the healthcare sector.² Their remarkable earnings have led to three decades of consistent dividend growth,³ giving West Pharmaceutical a well-earned place among other quality companies in the S&P 500® Dividend Aristocrats® Index.

West Pharmaceuticals vs. Index
Growth of \$10,000



Source: Bloomberg. 12/31/92-5/31/23

West Pharmaceutical is a great example of what it means to be a Dividend Aristocrat. Explore all the companies in the S&P 500 Dividend Aristocrats Index with the **ProShares S&P 500 Dividend Aristocrats ETF (NOBL)**.

¹ Source: West Pharmaceutical, Corporate Responsibility.
² Source: FactSet, five-year average ending in March 2023.
³ Source: ProShares.

Have Questions?

Financial professionals can contact ProShares at **866-776-5125** or email **info@proshares.com** for additional information about ProShares and other investment products.

NOBL
S&P 500 Dividend
Aristocrats

Holdings are subject to change. As of 5/31/23, NOBL included a 1.46% allocation to West Pharmaceutical Services.

This is not intended to be investment advice. Any forward-looking statements herein are based on expectations of ProShare Advisors LLC at this time.

There is no guarantee any ProShares ETF will achieve its investment objective.

Shares of any ETF are generally bought and sold at market price (not NAV) and are not individually redeemed from the fund. Your brokerage commissions will reduce returns.

Investing involves risk, including the possible loss of principal. This ProShares ETF is subject to certain risks, including the risk that the fund may not track the performance of the index and that the fund's market price may fluctuate, which may decrease performance. Please see the summary and full [prospectuses](#) for a more complete description of risks.

Carefully consider the investment objectives, risks, charges and expenses of ProShares before investing. This and other information can be found in their summary and full [prospectuses](#). Read them carefully before investing.

The "S&P 500[®] Dividend Aristocrats[®]" Index is a product of S&P Dow Jones Indices LLC and its affiliates and has been licensed for use by ProShares. "S&P[®]" is a registered trademark of Standard & Poor's Financial Services LLC ("S&P") and "Dow Jones[®]" is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones") and have been licensed for use by S&P Dow Jones Indices LLC and its affiliates. ProShares have not been passed on by S&P Dow Jones Indices LLC and its affiliates as to their legality or suitability. ProShares based on the S&P 500 Dividend Aristocrats Index are not sponsored, endorsed, sold or promoted by S&P Dow Jones Indices LLC, Dow Jones, S&P or their respective affiliates, and they make no representation regarding the advisability of investing in ProShares. **THESE ENTITIES AND THEIR AFFILIATES MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO PROSHARES.**

ProShares ETFs (ProShares Trust and ProShares Trust II) are distributed by SEI Investments Distribution Co., which is not affiliated with the funds' advisor or sponsor.

©2023 PSA BR-2023-5722964.1